Galectin Therapeutics Q2 EPS $(0.20) Misses $(0.16) Estimate
Benzinga Newsdesk 2 years ago
EarningsNews
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 33.33 percent decrease over losses of $(0.15) per share
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from the same period last year.